- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ginkgo Bioworks Holdings (DNA)
8.720
-0.650(-6.94%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.370
9.240
52 wk Range
5.370
17.580
DNA Earnings
View the latest Ginkgo Bioworks earnings results, revenue figures, and Ginkgo Bioworks earning report, including the Ginkgo Bioworks earnings dates and reported performance.
Latest Release
Aug 05, 2026
EPS / Forecast
-0.92 / -1.05
Revenue / Forecast
20M / 29.9M
All numbers in USD
Ginkgo Bioworks Holdings Earnings Call Summary for Q2/2026
- Q2 revenue fell 48% YoY to $20M, missing $29.9M consensus by 33%; adjusted EPS of -$0.92 beat estimates of -$1.05, but shares dropped 4.89% after-hours.
- Company reaffirmed FY2026 cash burn guidance of $125M-$150M; ended quarter with $389M total liquidity including restricted cash and $302M in cash equivalents.
- Ginkgo refocused strategy on autonomous laboratory technology after divesting biosecurity business in April, now operating as single segment with expanded Nebula system.
- Management declined to provide revenue guidance or segment breakdowns; plans to expand autonomous lab sales to biopharma, national labs, and universities while adding chemistry automation.
- CEO Kelly emphasized autonomous labs as competitive response to China in biotech; Q2 cash burn rose 18% to $45M while G&A expenses fell 26% from restructuring actions.
Last Updated: 2026-08-05, 07:04 p/m
Read Full TranscriptFAQ
What Is Ginkgo Bioworks's Earnings Per Share (TTM)?
The Ginkgo Bioworks EPS (TTM) is -5.380.
When Is The Next Ginkgo Bioworks Earnings Date?
Ginkgo Bioworks will release its next earnings report on Nov 16, 2026.
What Is Ginkgo Bioworks’s Revenue Forecasts For Upcoming Quarters?
Ginkgo Bioworks’s revenue forecast is 27.10M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.